欣脉胶囊(Xinmai Capsule) - 在研适应症：血脂障碍_专利_临床

概要

基本信息

药物类型

中药

别名-

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

血脂障碍

非在研适应症-

原研机构

中国药科大学

在研机构

中国药科大学

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

关联

1

项与欣脉胶囊相关的临床试验

CTR20140480 / Recruiting临床3期IIT

以血脂康胶囊和安慰剂为对照评价欣脉胶囊治疗血脂异常（痰瘀阻遏证）的随机、双盲、多中心临床研究

评价欣脉胶囊治疗血脂异常（痰瘀阻遏证）有效性及安全性。

开始日期-

申办/合作机构

中国药科大学

100 项与欣脉胶囊相关的临床结果

登录后查看更多信息

100 项与欣脉胶囊相关的转化医学

登录后查看更多信息

100 项与欣脉胶囊相关的专利（医药）

登录后查看更多信息

1

项与欣脉胶囊相关的文献（医药）

1995-08-01·Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

[Clinical and experimental study on inhibitory effect of sanhuang mixture on platelet aggregation].

Article

作者: Yan, J ; Huang, W M ; Xu, J

Sanhuang mixture (Xinmai capsule) is composed of Astragalus membranaceus, Coptis chinensis and Scutellaria baicalensis. It could inhibit platelet aggregation (PAG) induced by ADP in rats or by ADP and ADR in vivo. Patients with high PAG took Xinmai capsule for 4 weeks, the effective rate was 88.7%, which was same as the efficacy of aspirin 50 mg/day. In Syndrome Differentiation of TCM, the effective rate was the highest (92.3%) in the Syndrome of Qi Deficiency-Blood Stasis, and the lowest (72.7%) in the Syndrome of Stasis Phlegm and combined together.

100 项与欣脉胶囊相关的药物交易

登录后查看更多信息